Free tool
FAERS Monitor: Hemangeol
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 205410 or its brand name (Hemangeol, Propranolol Hydrochloride). Reports on generic versions are filed under their own applications.
Reports
15,795
Serious
8,000
51% of reports
Hospitalization
3,304
Death reported
1,476
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- off label use3,538
- drug ineffective1,369
- product use issue1,177
- product use in unapproved indication987
- nausea930
- inappropriate schedule of product administration914
- diarrhoea851
- product administered to patient of inappropriate age832
- headache799
- fatigue796
- toxicity to various agents695
- vomiting635
- drug intolerance616
- dyspnoea578
- condition aggravated562
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 99 |
| 2005 | 162 |
| 2006 | 127 |
| 2007 | 98 |
| 2008 | 79 |
| 2009 | 153 |
| 2010 | 174 |
| 2011 | 164 |
| 2012 | 203 |
| 2013 | 141 |
| 2014 | 146 |
| 2015 | 164 |
| 2016 | 296 |
| 2017 | 299 |
| 2018 | 524 |
| 2019 | 639 |
| 2020 | 1,084 |
| 2021 | 897 |
| 2022 | 1,990 |
| 2023 | 2,089 |
| 2024 | 2,693 |
| 2025 | 2,017 |
| 2026 | 1,557 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,038,364 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| product administered to patient of inappropriate ageSignal | 832 | 210.8 | 196.3 | 149,852 |
| drug intoleranceSignal | 616 | 8.5 | 7.9 | 4,085 |
| product use issueSignal | 1,177 | 8.4 | 7.9 | 7,670 |
| inappropriate schedule of product administrationSignal | 914 | 6.8 | 6.4 | 4,516 |
| toxicity to various agentsSignal | 695 | 5.5 | 5.1 | 2,569 |
| off label useSignal | 3,538 | 5.4 | 5.2 | 13,171 |
| product use in unapproved indicationSignal | 987 | 5.3 | 5.0 | 3,486 |
| condition aggravatedSignal | 562 | 2.5 | 2.3 | 494 |
| vomiting | 635 | 1.8 | 1.7 | 230 |
| diarrhoea | 851 | 1.8 | 1.6 | 285 |
| headache | 799 | 1.7 | 1.6 | 235 |
| nausea | 930 | 1.6 | 1.5 | 197 |
| drug ineffective | 1,369 | 1.4 | 1.3 | 155 |
| fatigue | 796 | 1.4 | 1.3 | 79 |
| dyspnoea | 578 | 1.4 | 1.3 | 56 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.